Brief: Revive Therapeutics provides corporate update
29/03/2017 12:00
March 29 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive Therapeutics provides corporate update
* Says has engaged with five clinical sites to advance phase
2 study of revenue-004 (bucillamine) in cystinuria
Source text for Eikon: ID:nCCN3Z7Km7
Further company coverage: RVV.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure